Federico Cappuzzo, MD, of Istituto Toscano Tumori-Ospedale Civile Livorno, and Tony Mok, MD, of The Chinese University of Hong Kong, discuss current strategies for treating patients with acquired resistance, and what the future holds for these patients.
Michael Pfreundschuh, MD, of Universitaetsklinikum des Saarlandes, summarizes a session he chaired on this topic, which covered Burkitt’s lymphoma as well as lymphoblastic leukemia in children and adults.
Frederic Amant, MD, PhD, of the Katholieke Universiteit Leuven, discusses the important decisions that must be made when a woman is diagnosed with cancer while pregnant: Should treatment be delayed or the pregnancy terminated?
Martine J. Piccart-Gebhart, MD, PhD, of the Jules Bordet Institute, discusses the ESMO initiative to make cancer drugs affordable.
Jean-Charles Soria, MD, PhD, of Gustave Roussy, summarizes an important study: afatinib vs erlotinib in squamous cell carcinoma of the lung.
Martine J. Piccart-Gebhart, MD, PhD, of the Jules Bordet Institute, and ECCO President, discusses ways in which imaging can form the solution to individualized cancer treatment.
